New drug Ronapreve is made available for treatment of NI Covid patients

A new drug is available for hospitalised patients with COVID-19 from this week.

Thursday, 23rd September 2021, 2:45 pm
Updated Thursday, 23rd September 2021, 3:05 pm
Health minister Robin Swann

Ronapreve is a combines two “neutralising monoclonal antibodies” (nMABs) called Casirivimab and Imdevimab.

It is the first neutralising antibody medicine specifically designed to treat Covid-19 to be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the UK.

NI health minister Robin Swann said: “This new treatment is incredibly welcome and will benefit some of the most vulnerable patients in our hospitals.

Sign up to our daily newsletter

The i newsletter cut through the noise

“Alongside the success of our vaccine roll out, the development of new therapeutics is an important step in saving lives, protecting our health service, and fighting back against COVID-19.”

Chief Medical Officer Professor Sir Michael McBride said: “The availability of Ronapreve will help us significantly as we continue to move through this pandemic.

“It will initially be targeted at those in hospital aged 50 and over, or are aged 12 to 49 and are considered to be immunocompromised, and have not mounted an antibody response against COVID-19.

“This will include individuals who are immunocompromised, such as patients with certain cancer or autoimmune diseases.”

More from the News Letter:

A message from the Editor:

Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.

With the coronavirus lockdown having a major impact on many of our advertisers - and consequently the revenue we receive - we are more reliant than ever on you taking out a digital subscription.

Subscribe to and enjoy unlimited access to the best Northern Ireland and UK news and information online and on our app. With a digital subscription, you can read more than 5 articles, see fewer ads, enjoy faster load times, and get access to exclusive newsletters and content. Visit to sign up.

Our journalism costs money and we rely on advertising, print and digital revenues to help to support them. By supporting us, we are able to support you in providing trusted, fact-checked content for this website.

Ben Lowry

Acting Editor